Trevi Therapeutics, Inc.
http://www.trevitherapeutics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Trevi Therapeutics, Inc.
Expert Panel On Surgical Robotics Expects Autonomous Systems To Democratize Surgery
Autonomous robotic systems that enhance the skillset of surgeons face a gradual evolution, the experts agreed.
Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019
With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery